BSE Live
Prev. Close
Open Price
Bid Price (Qty.)
()
Offer Price (Qty.)
()
NSE Live
Oct 29, 15:52Prev. Close
41.65
Open Price
42.20
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Balaxi Pharmaceuticals (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 0.65 | 3.55 | 16.17 | 14.67 | 15.13 | |
| Diluted EPS (Rs.) | 0.65 | 3.54 | 16.02 | 14.67 | 15.13 | |
| Cash EPS (Rs.) | 0.73 | 3.82 | 16.44 | 14.92 | 15.22 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 23.16 | 111.53 | 90.47 | 57.91 | 43.25 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 23.16 | 111.53 | 90.47 | 57.91 | 43.25 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 11.05 | 64.41 | 106.21 | 101.29 | 86.87 | |
| PBDIT/Share (Rs.) | 1.41 | 7.01 | 23.01 | 20.01 | 20.70 | |
| PBIT/Share (Rs.) | 1.33 | 6.54 | 22.50 | 19.76 | 20.61 | |
| PBT/Share (Rs.) | 0.96 | 5.12 | 22.05 | 19.70 | 20.60 | |
| Net Profit/Share (Rs.) | 0.65 | 3.35 | 15.93 | 14.67 | 15.13 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 12.79 | 10.87 | 21.66 | 19.75 | 23.82 | |
| PBIT Margin (%) | 12.04 | 10.14 | 21.18 | 19.50 | 23.72 | |
| PBT Margin (%) | 8.67 | 7.95 | 20.76 | 19.44 | 23.70 | |
| Net Profit Margin (%) | 5.90 | 5.20 | 15.00 | 14.48 | 17.42 | |
| Return on Networth / Equity (%) | 2.81 | 3.00 | 17.61 | 25.32 | 34.99 | |
| Return on Capital Employed (%) | 5.62 | 5.73 | 24.14 | 34.09 | 47.64 | |
| Return on Assets (%) | 2.06 | 2.36 | 12.50 | 17.90 | 21.95 | |
| Total Debt/Equity (X) | 0.24 | 0.11 | 0.12 | 0.03 | 0.08 | |
| Asset Turnover Ratio (%) | 0.37 | 0.49 | 1.02 | 1.34 | 126.04 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 2.73 | 4.09 | 2.84 | 2.26 | 1.90 | |
| Quick Ratio (X) | 2.73 | 4.06 | 2.80 | 2.26 | 1.90 | |
| Inventory Turnover Ratio (X) | 145.26 | 48.40 | 0.00 | 10,255.89 | 5,791.41 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 3.08 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 2.98 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 96.92 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 97.02 | 0.00 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 354.58 | 510.37 | 532.84 | 352.69 | 527.53 | |
| EV/Net Operating Revenue (X) | 5.81 | 7.27 | 4.93 | 3.48 | 6.07 | |
| EV/EBITDA (X) | 45.45 | 66.85 | 22.75 | 17.63 | 25.49 | |
| MarketCap/Net Operating Revenue (X) | 5.79 | 7.70 | 4.99 | 3.47 | 6.04 | |
| Retention Ratios (%) | 0.00 | 0.00 | 96.91 | 0.00 | 0.00 | |
| Price/BV (X) | 2.76 | 4.45 | 5.86 | 6.07 | 12.13 | |
| Price/Net Operating Revenue | 5.79 | 7.70 | 4.99 | 3.47 | 6.04 | |
| Earnings Yield | 0.01 | 0.01 | 0.03 | 0.04 | 0.03 |
12.08.2025
Balaxi Pharma Consolidated June 2025 Net Sales at Rs 70.74 crore, up 7.8% Y-o-Y
06.08.2025
Balaxi Pharma Standalone June 2025 Net Sales at Rs 16.71 crore, down 12.18% Y-o-Y
24.06.2025
Balaxi Pharma Standalone March 2025 Net Sales at Rs 9.65 crore, down 39.33% Y-o-Y
20.02.2025
Balaxi Pharma Consolidated December 2024 Net Sales at Rs 73.29 crore, up 20.57% Y-o-Y
12.08.2025
Balaxi Pharma Consolidated June 2025 Net Sales at Rs 70.74 crore, up 7.8% Y-o-Y
06.08.2025
Balaxi Pharma Standalone June 2025 Net Sales at Rs 16.71 crore, down 12.18% Y-o-Y
24.06.2025
Balaxi Pharma Standalone March 2025 Net Sales at Rs 9.65 crore, down 39.33% Y-o-Y
20.02.2025
Balaxi Pharma Consolidated December 2024 Net Sales at Rs 73.29 crore, up 20.57% Y-o-Y
15.06.2017
24.04.2017
18.04.2017
18.04.2017
14.02.2017
13.02.2017
12.02.2017
09.12.2016